Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib Sodium (Macugen) for Proliferative Diabetic Retinopathy
NCT01486771Phase 4Unknown
- Sponsor
- Valley Retina Institute
- Start
- Nov 2007
- Primary completion
- Aug 2013
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 4, randomised trial of pegaptanib sodium in proliferative diabetic retinopathy (PDR) (3 arms), sponsored by Valley Retina Institute. Primary endpoint: Regression of high risk proliferative diabetic retinopathy at 54 weeks. Status: unknown.
02
Drugs
pegaptanib sodium
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT01486771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486771.